中证智能财讯迈得医疗（688310）1月26日晚间披露2025年度业绩预告，预计2025年归母净利润6652.13万元，上年同期亏损1998.12万元；扣非净利润预计 5463.95万元，上年同期亏损2628.09万元。以1月26日收盘价计算，迈得医疗目前市盈率（TTM）约为40.63倍，市净率（LF）约3.35倍，市销率（TTM）约 9.66倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 200 @ 20 100 300 50 47624 40919 To83 29877 32x43 29.54 224 0 -50 -100 -150 2022-06-30 2021-12-37 2021-06-30 ' 2020-12-37 2022-12-37 <3-12-37 3-06-30 2n. -○- 公司 -○- 行业均值 100 ହ 90 80 70 63 69 60 50 (8 40 30 2 20 15086 15 10 AR 0 2027-12-37 | 2022-72-37 1 2020-12-37 1 2021-06-30 ' 023-12-37 ...

Group 1 - Evert plans to acquire equity in Shengpu Co., with stock suspension starting January 27, 2026, expected to last no more than 10 trading days [5] - Haike New Source signed a long-term cooperation agreement with BYD Lithium Battery to supply at least 100,000 tons of electrolyte solvent annually for three years [5] - Sanxiang Bio has developed a CE-certified Nipah virus nucleic acid testing kit and a domestic research version, responding to the Nipah virus outbreak in India [9][10] Group 2 - Sangfor Health expects a Q4 net profit of approximately 2.5 billion yuan, a 1097% increase from the previous quarter, driven by a significant payment from Pfizer for the 707 project [2] - Puran Co. anticipates a Q4 net profit of about 1.46 billion yuan, a 696% increase from Q3, despite an annual decrease of approximately 29.89% [3][4] - Chip Source Micro expects a net profit of 52 million to 76 million yuan for 2025, a decrease of 62.53% to 74.36% year-on-year due to increased costs and reduced other income [6] Group 3 - Maide Medical forecasts a net profit of approximately 66.5 million yuan for 2025, marking a turnaround from losses in the previous year [7] - Ruixin Micro expects a net profit of 1.023 billion to 1.103 billion yuan for 2025, representing a growth of 71.97% to 85.42% year-on-year [8] - Qingda Environmental anticipates a net profit of 165 million to 190 million yuan for 2025, an increase of 77.47% to 104.36% year-on-year [10] Group 4 - Jiangxun Technology expects a net profit increase of approximately 86.44% for 2025, reaching around 156 million yuan [11] - Micron Bio anticipates a net profit of approximately 53.5 million yuan for 2025, achieving profitability after previous losses [11] - Blue Special Optics forecasts a net profit of 375 million to 400 million yuan for 2025, a growth of 70.04% to 81.38% year-on-year [13]

Core Viewpoint - The company expects a significant increase in net profit for the year 2025, projecting approximately 66.52 million yuan, driven by substantial growth in overall operating revenue and successful product delivery [1] Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of approximately 66.52 million yuan for the year 2025 [1] - The increase in revenue is attributed to the orderly implementation of production plans and a focus on technological innovation and process iteration [1] - The blood purification and drug-device combination intelligent equipment business is performing well, particularly due to strong demand growth in the terminal market for medical consumables [1] Group 2: Q3 Financial Results - For the first three quarters of 2025, the company's main revenue reached 225 million yuan, a year-on-year increase of 2.31% [2] - The net profit attributable to shareholders for the same period was 8.84 million yuan, reflecting a year-on-year increase of 15.82% [2] - In Q3 2025 alone, the company reported a main revenue of 83.64 million yuan, a significant year-on-year increase of 54.38% [2] - The net profit for Q3 2025 was 2.79 million yuan, showing a remarkable year-on-year increase of 224.07% [2] - The company reported a debt ratio of 29.86% and a gross profit margin of 40.19% [2]

证券之星消息，迈得医疗发布业绩预告，预计2025年全年扣非后净利润盈利约5463.95万元。 公告中解释本次业绩变动的原因为： 迈得医疗2025年三季报显示，前三季度公司主营收入2.25亿元，同比上升2.31%；归母净利润883.67万 元，同比上升15.82%；扣非净利润-127.85万元，同比下降526.58%；其中2025年第三季度，公司单季度 主营收入8364.3万元，同比上升54.38%；单季度归母净利润279.16万元，同比上升224.07%；单季度扣 非净利润123.64万元，同比上升118.23%；负债率29.86%，投资收益16.76万元，财务费用-52.36万元， 毛利率40.19%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 2025年度,公司整体营业收入实现大幅增长,主要系公司统筹推进生产计划有序落地,保障了产品有效交付, 并且坚持技术创新与工艺迭代双轮驱动,持续强化产品竞争力与市场影响力,血液净化类和药械组合类智 能装备业务发展良好,尤其得益于药械组合类医用耗材在终端市场展现出良好的需求增长态势,对应 ...

迈得医疗2025年三季报显示，前三季度公司主营收入2.25亿元，同比上升2.31%；归母净利润883.67万 元，同比上升15.82%；扣非净利润-127.85万元，同比下降526.58%；其中2025年第三季度，公司单季度 主营收入8364.3万元，同比上升54.38%；单季度归母净利润279.16万元，同比上升224.07%；单季度扣 非净利润123.64万元，同比上升118.23%；负债率29.86%，投资收益16.76万元，财务费用-52.36万元， 毛利率40.19%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公告中解释本次业绩变动的原因为： 2025年度,公司整体营业收入实现大幅增长,主要系公司统筹推进生产计划有序落地,保障了产品有效交付, 并且坚持技术创新与工艺迭代双轮驱动,持续强化产品竞争力与市场影响力,血液净化类和药械组合类智 能装备业务发展良好,尤其得益于药械组合类医用耗材在终端市场展现出良好的需求增长态势,对应药械 组合类智能装备市场需求前景乐观,公司重点围绕药械组合类智能装备展开新产品研发和市场开拓, ...

迈得医疗(688310.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润与上年同期(法 定披露数据)相比，将实现扭亏为盈，实现归属于母公司所有者的净利润6652.13万元左右。 ...

智通财经APP讯，迈得医疗(688310.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润与上年同期(法定披露数据)相比，将实现扭亏为盈，实现归属于母公司所有者的净利润6652.13万元 左右。 ...

（记者 曾健辉） 每经AI快讯，迈得医疗1月26日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 与上年同期相比，将实现扭亏为盈，实现归属于母公司所有者的净利润6652.13万元左右。业绩变动主 要原因是，2025年度，公司整体营业收入实现大幅增长，主要系公司统筹推进生产计划有序落地，保障 了产品有效交付，并且坚持技术创新与工艺迭代双轮驱动，持续强化产品竞争力与市场影响力，血液净 化类和药械组合类智能装备业务发展良好，尤其得益于药械组合类医用耗材在终端市场展现出良好的需 求增长态势，对应药械组合类智能装备市场需求前景乐观，公司重点围绕药械组合类智能装备展开新产 品研发和市场开拓，本期药械组合类智能装备收入实现较大增长。 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 ...

Core Viewpoint - The company, Maide Medical (688310.SH), is expected to achieve significant revenue growth in 2025, with projected revenue of approximately 447 million yuan, representing an increase of about 173 million yuan or 62.81% year-on-year [1] Financial Performance - The company anticipates turning a profit in 2025, with a projected net profit attributable to shareholders of approximately 66.52 million yuan [1] - The expected net profit, excluding non-recurring gains and losses, is around 54.64 million yuan [1] Business Growth Drivers - The substantial revenue growth is attributed to the orderly implementation of production plans, ensuring effective product delivery [1] - The company emphasizes technological innovation and process iteration to enhance product competitiveness and market influence [1] - The blood purification and medical device combination intelligent equipment sectors are performing well, particularly due to strong demand growth for medical consumables in the end market [1] - The optimistic market outlook for medical device combination intelligent equipment has led the company to focus on new product development and market expansion in this area [1]

证券代码：688310 证券简称：迈得医疗 公告编号：2026-007 迈得医疗工业设备股份有限公司 二、上年同期业绩情况和财务状况 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计迈得医疗工业设备股份有限公司（以下简称"公 司"）2025 年年度实现营业收入 44,749.77 万元左右，与上年同期（法定披露数 据）相比，将增加 17,264.69 万元左右，同比增加 62.81%左右。 2、预计 2025 年年度实现归属于母公司所有者的净利润与上年同期（法定披 露数据）相比，将实现扭亏为盈，实现归属于母公司所有者的净利润 6,652.13 万元左右。 3、预计 2025 年年度实现归属于母公司所有者扣除非经常性损益的净利润 5,463.95 万元左右。 （三）本次业绩预告未经注册会计师审计。 （一）利润总额：-2,923.18 万元。 归 ...